We are live on ! Find out more
BIAF icon

bioAffinity Technologies
BIAF

5 hedge funds and large institutions have $177K invested in bioAffinity Technologies in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 5 → 5 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.09% less ownership

Funds ownership: 1.22% → 1.13% (-0.09%)

80% less capital inflows, than outflows

Capital inflows: $2.48K | Capital outflows: $12.4K

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$2.48K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
-$8.28K
2
UBS Group
UBS Group
Switzerland
-$4.14K

BIAF Hedge Fund Activity: Q2 2023 in Review

5 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAF) for Q2 2023, worth a combined $177K — down 8.5% from $193K a quarter earlier.

Fund positioning in BIAF was balanced in Q2 2023: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.

The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $2.48K. The largest seller was Two Sigma Investments, cutting an estimated $8.28K.

  • 5 institutional investors held bioAffinity Technologies (BIAF) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $177K of bioAffinity Technologies stock for Q2 2023, down 8.5% quarter-over-quarter.
  • 1 fund opened new bioAffinity Technologies positions in Q2 2023 and 1 closed out, a net change of 0 holders.
  • The largest bioAffinity Technologies buyer in Q2 2023 was Tower Research Capital (TRC), an estimated $2.48K added.
  • The largest bioAffinity Technologies seller in Q2 2023 was Two Sigma Investments, an estimated $8.28K sold.

Based on aggregated 13F filings for Q2 2023.